Last update 14 Dec 2024
Teriparatide biosimilar(Accord Healthcare S.L.U.)
Last update 14 Dec 2024
Overview
Basic Info
Drug Type Recombinant polypeptide, Biosimilar |
Synonyms teriparatide biosimilar(Accord Healthcare S.L.U.), Sondelbay |
Target |
Mechanism PTH1R agonists(Parathyroid hormone receptor agonists), Osteogenesis stimulants, Parathyroid hormone replacements |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date |
Regulation- |
Login to view timeline
Gene Sequence
Sequence Code 4953
The sequence is quoted from: *****
Related
1
Clinical Trials associated with Teriparatide biosimilar(Accord Healthcare S.L.U.)An Assessor-Blind, Randomized, Three-Treatment, Three-Period, Single-Dose, Crossover, Bioequivalence Study of INTG8of Intas Pharmaceuticals Limited, India to Forteo® (Lilly USA,LLC) and Forsteo® (Eli Lilly Nederland B.V., The Netherlands)in Healthy Men and Postmenopausal Women after SubcutaneousAdministration
100 Clinical Results associated with Teriparatide biosimilar(Accord Healthcare S.L.U.)
Login to view more data
100 Translational Medicine associated with Teriparatide biosimilar(Accord Healthcare S.L.U.)
Login to view more data
100 Patents (Medical) associated with Teriparatide biosimilar(Accord Healthcare S.L.U.)
Login to view more data
100 Deals associated with Teriparatide biosimilar(Accord Healthcare S.L.U.)
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Glucocorticoid-induced osteoporosis | EU | 24 Mar 2022 | |
| Glucocorticoid-induced osteoporosis | IS | 24 Mar 2022 | |
| Glucocorticoid-induced osteoporosis | LI | 24 Mar 2022 | |
| Glucocorticoid-induced osteoporosis | NO | 24 Mar 2022 | |
| Osteoporosis, Postmenopausal | EU | 24 Mar 2022 | |
| Osteoporosis, Postmenopausal | IS | 24 Mar 2022 | |
| Osteoporosis, Postmenopausal | LI | 24 Mar 2022 | |
| Osteoporosis, Postmenopausal | NO | 24 Mar 2022 | |
| Osteoporotic Fractures | EU | 24 Mar 2022 | |
| Osteoporotic Fractures | IS | 24 Mar 2022 | |
| Osteoporotic Fractures | LI | 24 Mar 2022 | |
| Osteoporotic Fractures | NO | 24 Mar 2022 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Osteoporosis | Phase 3 | IN | 26 Oct 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free